JP

Jonathan P. Arm

Chief Financial Officer

Intensity Therapeutics

Therapeutic Areas

Intensity Therapeutics Pipeline

DrugIndicationPhase
INT230-6Metastatic Soft Tissue SarcomasPhase 2/3